Physician profile
Gary B Langnas
NPI 1063496818
$6,828.03
in general payments reported to CMS, 2019-2025
54 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $811 · 2021: $1,883 · 2022: $911 · 2023: $889 · 2024: $610 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,688.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $905.58 | 2019-2025 | |
| Novo Nordisk INC | $825.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $592.05 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $469.64 | 2021-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $463.82 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $396.93 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.14 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $274.37 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.27 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $202.62 | 2020-2021 | |
| Exact Sciences Corporation | $163.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $154.80 | 2021 | |
| Merck Sharp & Dohme LLC | $124.11 | 2021-2023 | Dificid |
| Kowa Pharmaceuticals America, INC. | $119.00 | 2020-2022 | |
| Boston Scientific Corporation | $116.78 | 2022-2023 | Watchman Flx, Watchman Access System |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Langnas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.